Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986278

Next Previous
X
Search
Drug Profile

BMS 986278

Alternative Names: BMS-986278

Latest Information Update: 13 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antifibrotics; Carbamates; Cyclohexanecarboxylic acids; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Pulmonary fibrosis
  • Phase I Liver disorders

Most Recent Events

  • 09 Dec 2024 BMS plans a phase-I trial for Kidney-disorders (In volunteers) in USA (Unspecified), (NCT06723535),
  • 04 Dec 2024 Bristol-Myers Squibb plans a phase I comparative bioavailability trial in healthy volunteers (PO) in December 2024 (NCT06715683)
  • 19 Sep 2024 Bristol-Myers Squibb initiates a phase I drug interaction and pharmacokinetic trial (In volunteers) in USA (PO)(NCT06568458)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top